Fergus Sweeney

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND Stakeholders across the clinical trial enterprise have expressed concern that the current clinical trial enterprise is unsustainable. The cost and complexity of trials have continued to increase, threatening our ability to generate reliable evidence essential for making appropriate decisions concerning the benefits and harms associated with(More)
Evidence generated from randomized controlled trials forms the foundation of cardiovascular therapeutics and has led to the adoption of numerous drugs and devices that prolong survival and reduce morbidity, as well as the avoidance of interventions that have been shown to be ineffective or even unsafe. Many aspects of cardiovascular research have evolved(More)
‘results section’ to be added to this register. How is this coming along? Guidance on the ‘results section’ has to be completed, agreed and published by the EC, which I anticipate will happen by the end of this year. We then have to develop the software, which is currently planned to happen for the end of next year. But we’ll have to see how other demands(More)
  • 1